Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05091372 · ClinicalTrials.gov registry record · Phase 2
Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma
A Phase 2 study of Myeloma Multiple, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 94
- Enrollment target
- 1
- Study location
NCT05091372: Recruiting Phase 2 study of Myeloma Multiple, sponsored by M.D. Anderson Cancer Center.
NCT05091372 is a Phase 2 study of Myeloma Multiple that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 94 participants, above the 73-participant average among 7 other Myeloma Multiple trials with a reported enrollment target (29% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05091372, a Phase 2 study of Myeloma Multiple, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 94 participants
- Enrollment target
- 1
- Study location
Study Summary
To increase the conversion rate from MRD-positive to MRD-negative CR in patients with newly diagnosed multiple myeloma (NDMM) receiving post-transplant maintenance therapy with belantamab mafodotin plus lenalidomide.
Conditions Studied
Interventions
- DRUG Belantamab mafodotin
- DRUG Lenalidomide
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2022-12-01 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 2 |
What NCT05091372 shows while recruiting
NCT05091372 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 94 participants, a relatively small participant target, above the 73-participant average among 7 other Myeloma Multiple trials with a reported enrollment target (29% higher).
The record links to 1 condition, with Myeloma Multiple appearing as the primary indexed condition, and to 2 interventions - of which Belantamab mafodotin is the first listed.
NCT05091372 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05091372 about?
NCT05091372 is a clinical study titled "Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma". To increase the conversion rate from MRD-positive to MRD-negative CR in patients with newly diagnosed multiple myeloma (NDMM) receiving post-transplant maintenance therapy with belantamab mafodotin plus lenalidomide.
What is the current status of trial NCT05091372?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 94 participants. The study started on 2022-12-01. Estimated completion is 2027-12-31.
What conditions does trial NCT05091372 study?
This clinical trial studies the following conditions: Myeloma Multiple.
What interventions are being tested in trial NCT05091372?
The interventions under investigation include: Belantamab mafodotin (DRUG), Lenalidomide (DRUG).
Who is sponsoring clinical trial NCT05091372?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05091372 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myeloma Multiple
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Limited-duration Teclistamab
RECRUITING · Phase 2
-
Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 2
-
Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM
ACTIVE NOT RECRUITING · Phase 2
-
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
RECRUITING · Phase 1
-
T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 1
-
T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03747146 · 94 participants · NA
Enhanced Recovery After Surgery (ERAS) Total Knee Replacement (TKR) With a Transitional Pain Service
- NCT04061421 · 94 participants · Phase 1
Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)
- NCT04205968 · 94 participants · Phase 2
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
- NCT04464759 · 94 participants · Phase 1
A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI